Resultados de procura - Max Sauter

  • Mostrando 1 - 6 Resultados de 6
Limitar resultados
  1. 1
    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs

    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs por Grant Sugiura, Helen Kühn, Max Sauter, Uwe Haberkorn, Walter Mier

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers

    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers por Felicitas Stoll, Salvatore Amato, Max Sauter, Jürgen Burhenne, Johanna Weiß, Walter E. Haefeli, Antje Blank

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display

    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display por Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Jürgen Debus, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC

    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC por Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn, Annette Altmann

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC por Xu Zhou, Jingyu An, Roma Kurilov, Benedikt Brors, Kai Hu, Teresa Peccerella, Stephanie Roessler, Katrin Pfütze, Angela Schulz, Stephan Wolf, Nicolas Hohmann, Dirk Theile, Max Sauter, Jürgen Burhenne, Shigenori Ei, Ulrike Heger, Oliver Strobel, Simon T. Barry, Christoph Springfeld, Christine Tjaden, Frank Bergmann, Markus W. Büchler, Thilo Hackert, Franco Fortunato, John P. Neoptolemos, Peter J. Bailey

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models por Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F. Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Theo Schmitt, Kathrin I. Foerster, Jürgen Burhenne, Walter E. Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M. van Tilburg, David Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: